Camptothecin (CPT) is a potent inhibitor of cell proliferation, and camptothecin derivatives, such as irinotecan and topotecan, have proven valuable in treatment of solid tumors. The goal of this project to develop a clearer mechanistic and molecular understanding of repair of CPT-induced DNA damage, and to apply this knowledge to developing a rapid assay for CPT-sensitivity based on repair capability. We propose three specific aims to that end. (1) We will determine the molecular mechanism by which MRE11 contributes to repair of CPT-induced DNA damage. (2) We will elucidate the roles of RecQ family helicases and G4 DNA in CPT sensitivity. (3) We will test the utility of y-sH2AX as a biomarker for chemotherapeutic sensitivity and DNA repair. The results of the proposed research will provide an important step toward improved treatment of cancer based on stratification of tumor response to CPT.

Public Health Relevance

By applying basic understanding of DNA repair mechanisms to cancer therapy, the proposed research will define an opportunity for personalized medicine which has not heretofore been exploited, and provide a guide for stratification of tumors based on response to chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA077852-15
Application #
8494584
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$253,608
Indirect Cost
$71,026
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Welcsh, Piri; Kehrli, Keffy; Lazarchuk, Pavlo et al. (2016) Application of the microfluidic-assisted replication track analysis to measure DNA repair in human and mouse cells. Methods 108:99-110
Tokita, Mari; Kennedy, Scott R; Risques, Rosa Ana et al. (2016) Werner syndrome through the lens of tissue and tumour genomics. Sci Rep 6:32038
Loeb, Lawrence A (2016) Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences. Cancer Res 76:2057-9
Reid-Bayliss, Kate S; Arron, Sarah T; Loeb, Lawrence A et al. (2016) Why Cockayne syndrome patients do not get cancer despite their DNA repair deficiency. Proc Natl Acad Sci U S A 113:10151-6
Bosch, Linda J W; Luo, Yanxin; Lao, Victoria V et al. (2016) WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. Clin Cancer Res 22:4612-22
Cohen, Stacey A; Wu, Chen; Yu, Ming et al. (2016) Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Clin Colorectal Cancer 15:164-9
Ahn, Eun Hyun; Lee, Seung Hyuk; Kim, Joon Yup et al. (2016) Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells. Cancer Res 76:4569-78
Tang, Weiliang; Robles, Ana I; Beyer, Richard P et al. (2016) The Werner syndrome RECQ helicase targets G4 DNA in human cells to modulate transcription. Hum Mol Genet 25:2060-2069
Fox, Edward J; Salk, Jesse J; Loeb, Lawrence A (2016) Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer. Genome Med 8:30
Kehrli, Keffy; Phelps, Michael; Lazarchuk, Pavlo et al. (2016) Class I Histone Deacetylase HDAC1 and WRN RECQ Helicase Contribute Additively to Protect Replication Forks upon Hydroxyurea-induced Arrest. J Biol Chem 291:24487-24503

Showing the most recent 10 out of 120 publications